Search - tctmd.com

Displaying 221 - 240 of 315

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for August 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

August 31, 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

News Conference News ESC 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

August 30, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

Women With A-fib Less Likely to Get Oral Anticoagulants Regardless of Risk

News Daily News

Women With A-fib Less Likely to Get Oral Anticoagulants Regardless of Risk

August 03, 2017

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

Pregnancy-Associated SCAD Is a Particularly High-Risk Subset of the Condition

News Daily News

Pregnancy-Associated SCAD Is a Particularly High-Risk Subset of the Condition

July 17, 2017

Episode 22: The A-fib and ACS Overlap

Podcast TCTMD Talking Points

Episode 22: The A-fib and ACS Overlap

June 14, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Prevalence, Management, and Long-term (6-Year) Outcomes of A-fib Among Patients Receiving DES

Presentation

Prevalence, Management, and Long-term (6-Year) Outcomes of A-fib Among Patients Receiving DES

May 23, 2017

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

May 11, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

News Daily News

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

March 28, 2017

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

News Conference News ISC 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

March 01, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.